JNJ

235.7

+0.74%↑

UNH

275.15

-1.93%↓

TMO

568.64

-0.99%↓

ABT

109.09

+0.67%↑

ISRG

475.33

-1.55%↓

JNJ

235.7

+0.74%↑

UNH

275.15

-1.93%↓

TMO

568.64

-0.99%↓

ABT

109.09

+0.67%↑

ISRG

475.33

-1.55%↓

JNJ

235.7

+0.74%↑

UNH

275.15

-1.93%↓

TMO

568.64

-0.99%↓

ABT

109.09

+0.67%↑

ISRG

475.33

-1.55%↓

JNJ

235.7

+0.74%↑

UNH

275.15

-1.93%↓

TMO

568.64

-0.99%↓

ABT

109.09

+0.67%↑

ISRG

475.33

-1.55%↓

JNJ

235.7

+0.74%↑

UNH

275.15

-1.93%↓

TMO

568.64

-0.99%↓

ABT

109.09

+0.67%↑

ISRG

475.33

-1.55%↓

Inicio・Lista de Acciones・Harmony Biosciences Holdings Inc

Harmony Biosciences Holdings Inc

Abierto

SectorSalud

37.09 -1.3

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

36.37

Máximo

37.76

Métricas clave
By Trading Economics
Ingresos	11M 51M
Ventas	39M 239M
P/B Media del Sector	11.937 84.243
BPA	1.08
Margen de beneficio	21.242
Empleados	268
EBITDA	14M 73M

Recomendaciones
By TipRanks
Recomendaciones	Comprar
Estimación a 12 meses	+15.62% upside

Dividendos
By Dow Jones
Próximas Ganancias	24 feb 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización de Mercado	492M 2.2B
Apertura anterior	38.39
Cierre anterior	37.09

Noticias sobre sentimiento de mercado

By Acuity

40%

60%

125 / 352 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Weak Bullish Evidence

29.8 / N/A Soporte y Resistencia

Harmony Biosciences Holdings Inc Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

3 feb 2026, 23:11 UTC

Principales Movimientos del Mercado

Adquisiciones, fusiones, absorciones

Silicon Laboratories Shares Up On Report of $7 Billion Texas Instruments Acquisition Deal

3 feb 2026, 23:50 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

3 feb 2026, 23:50 UTC

Charlas de Mercado

Nikkei May Decline After Hitting All-Time High -- Market Talk

3 feb 2026, 23:42 UTC

Charlas de Mercado

Gold Edges Lower on Possible Technical Correction -- Market Talk

3 feb 2026, 23:41 UTC

Adquisiciones, fusiones, absorciones

KKR Makes AI Play With $10.9B Asia Data-Center Deal

3 feb 2026, 23:38 UTC

Ganancias

AMD Sales Climb on Help From Data-Center Business -- Update

3 feb 2026, 23:29 UTC

Adquisiciones, fusiones, absorciones

KKR-Consortium Deal in STT GDC Is One of the Largest Digital-Infrastructure Transactions in Southeast Asia

3 feb 2026, 23:27 UTC

Adquisiciones, fusiones, absorciones

Netflix, Warner Defend Proposed Deal in Senate Hearing -- WSJ

3 feb 2026, 23:25 UTC

Adquisiciones, fusiones, absorciones

KKR-Consortium Expects Deal to Close by Early 2H of 2026

3 feb 2026, 23:23 UTC

Adquisiciones, fusiones, absorciones

KKR Consortium With Singtel to Own 75% and 25% Stake in ST Telemedia Global Data Centres

3 feb 2026, 23:22 UTC

Adquisiciones, fusiones, absorciones

KKR-Led Consortium to Buy Singapore-Based Global Data-Center Provider Valued at S$13.8B

3 feb 2026, 23:19 UTC

Charlas de Mercado

Australia Gold Miners Tipped to Rally Higher -- Market Talk

3 feb 2026, 23:19 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

3 feb 2026, 22:56 UTC

Principales Movimientos del Mercado

Adquisiciones, fusiones, absorciones

Silicon Laboratories Shares Up On Report of $7B Texas Instruments Acquisition Deal

3 feb 2026, 22:40 UTC

Ganancias

Amdocs Extends Collaboration With T-Mobile

3 feb 2026, 22:39 UTC

Ganancias

Amdocs 1Q Adj EPS $1.81

3 feb 2026, 22:39 UTC

Ganancias

Amdocs 1Q Rev $1.16B

3 feb 2026, 22:39 UTC

Ganancias

Amdocs 1Q EPS $1.45 >

3 feb 2026, 22:38 UTC

Ganancias

Amdocs: Shimie Hortig to Succeed Shuky Sheffer as President and CEO, Effective March 31

3 feb 2026, 22:30 UTC

Adquisiciones, fusiones, absorciones

Bob Iger's Second Time as CEO Wasn't Great for the Stock. He Still Leaves Behind A Strong Legacy. -- Barrons.com

3 feb 2026, 22:22 UTC

Adquisiciones, fusiones, absorciones

Texas Instruments Nearing $7B Deal for Silicon Laboratories, Sources Tell FT

3 feb 2026, 22:14 UTC

Ganancias

AMD Expects to Scale AI Business to Tens of Billions in Annual Sales in 2027, CEO Says

3 feb 2026, 22:13 UTC

Ganancias

AMD Expects Data-Center Unit Sales to Jump More Than 60% a Year Over Next Three to Five Years, CEO Says

3 feb 2026, 22:12 UTC

Ganancias

AMD in Talks With Several Companies About At-Scale, Multi-Year Chip Deployments, CEO Says

3 feb 2026, 22:10 UTC

Ganancias

AMD CEO: Eight of 10 Biggest AI Companies Use Instinct Chip to Power Production Workloads

3 feb 2026, 22:10 UTC

Ganancias

Blackstone Stock, Alternative Managers, BDCs Dive as Software Woes Infect Private Credit -- Barrons.com

3 feb 2026, 22:10 UTC

Charlas de Mercado

Key Drivers Underpinning Shaw's Bullish View of Gold Intact -- Market Talk

3 feb 2026, 22:10 UTC

Ganancias

AMD CEO: Enterprises Are Modernizing Data Centers to Have Compute Needed for New AI Workflows

3 feb 2026, 22:09 UTC

Ganancias

AMD CEO: Hyperscalers Expanding Infrastructure to Meet Growing Cloud-Services Demand in AI

3 feb 2026, 22:09 UTC

Ganancias

AMD CEO: Demand Accelerated Across Data Center, Gaming and PC

Comparación entre iguales

Cambio de precio

Harmony Biosciences Holdings Inc Esperado

Precio Objetivo

By TipRanks

15.62% repunte

Estimación a 12 meses

Media 43.75 USD 15.62%

Máximo 55 USD

Mínimo 32 USD

De acuerdo con 5 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Harmony Biosciences Holdings Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

5 ratings

Comprar

Mantener

Vender

De acuerdo con 5 analistas que ofrecen calificaciones bursátiles a para Harmony Biosciences Holdings Inc Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

29.8 / N/ASoporte y Resistencia

Bullish events outweigh bearish events.

Recent bullish events outweigh bearish events.

All events are bearish.

Sentimiento

By Acuity

125 / 352 Clasificación en Salud

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Harmony Biosciences Holdings Inc

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also offers HBS-102, a melanin-concentrating hormone receptor 1 for MCH neurons. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.